ap 5

AP5 is a potent and selective agonist for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49 nM against the GPR40 receptor.

DL-AP5 Sodium salt is a NMDA receptor antagonist.

L-AP5 is a NMDA antagonist.

AP5 sodium is a selective, potent, orally active GPR40 receptor agonist that exhibits positive allosteric modulation of endogenous ligands (AgoPAM). sodium exhibits potential for the study of type II diabetes.

D-AP5 (D-APV) is an NMDA receptor antagonist.

DL-AP5 is the racemic form of a selective N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant effects.

NPEC-caged-D-AP5 is a NMDA receptor antagonist.

Ap5A (Diadenosine pentaphosphate) is a polyphosphate diadenosine compound that functions as an adenylate kinase inhibitor, with a Ki value of 2.5 nM. This compound is applicable in cancer research.

Ap5dT is an inhibitor of cytosolic thymidine kinase and mitochondrial enzyme, with Ki values of 0.12 μM and 0.50 μM, respectively. This compound is utilized in research related to acute myeloid leukemia.

AP-C5 is a compound with selective inhibition of guanosine 3',5' cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), with a Pic50 value of 7.2 for cGMP, and can be used in the study of diarrheal diseases.

5Me3F4AP is an effective potassium channel blocker, with an IC50 ranging from 220 μM to 693 μM as the pH increases from 6.4 to 9.1. It has the potential to cross the blood-brain barrier and may be used in positron emission tomography (PET).

α1A-adrenoceptor antagonist

AP521 is an agonist of the human 5-HT1A receptor (IC50: 94 nM).

AP-521, a 5-HT1A receptor antagonist, is used potentially for the treatment of anxiety.

(S)-SNAP5114 is a selective inhibitor of GABA transport, exhibiting IC50 values of 5 μM for hGAT-3 and 21 μM for rGAT-2, and possesses anticonvulsant properties.

DL-AP5 (2-APV) lithium is a competitive antagonist of the NMDA (N-Methyl-D-aspartate) receptor. It exhibits notable analgesic activity and specifically blocks channels in the rabbit retina.

PAP508 is a PROTAC specifically targeting AR (Androgen Receptor).

AP-503 is a selective agonist of GPR133/ADGRD1, with an EC50 of 1.21 nM. It is utilized in research for preventing muscle-related disorders and vestibular dysfunction diseases.

CAP-53194 is a selective Plk1 inhibitor.

ONO 1301 is a prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase, and it suppresses pancreatic fibrosis in the DBTC-induced chronic pancreatitis model by inhibiting monocyte activity through both direct effects of ONO 1301 and induction of hepatocyte growth factor. ONO 1301 also promoting HGF synthesis and elevating intracellular cyclic AMP levels via IP-receptor signaling, highlighting its therapeutic relevance in fibrotic disease and inflammation research.

SNAP-5089 is a highly selective alpha1A-adrenoceptor antagonist.

H-Ser-Phe-Leu-Leu-Arg-OH, also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is utilized in coronary heart disease (CHD) research.

TRAP-5 amide is a peptide agonist for protease-activated receptor 1 (PAR 1) [1].

12(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of platelet or leukocyte 12-lipoxygenase (12-LO) on arachidonic acid. It activates human blood leukocyte 5-LOE. 12(S)-HpETE is the mediator of many biological functions, including induction of c-fos and c-jun, activation of AP-1, and endothelium-dependent vasoconstriction. It mediates the inhibitory synaptic response to FMRF-amide in Aplysia sensory neurons and inhibits Ca2+/calmodulin-dependent protein kinase II from rat brain cortex.